上海荣泰健康科技股份有限公司 2024 年第二次临时股东大会 会议资料 中国·上海 二〇二四年九月 现场会议：2024 年 9 月 13 日（星期五）14：00 网络投票：2024 年 9 月 13 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间段，即 9:15-9:25，9:30-11:30，13:00-15:00；通过互联 网投票平台的投票时间为股东大会召开当日的 9:15-15:00。 涉及融资融券、转融通业务、约定购回业务相关账户以及沪股通投资者的投 票，应按照《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等有 关规定执行。 二、现场会议地点 上海荣泰健康科技股份有限公司 2024 年第二次临时股东大会会议资料 上海荣泰健康科技股份有限公司 2024 年第二次临时股东大会会议议程 一、会议时间 4、审议《关于公司修订<董事会议事规则>的议案》； 5、审议《关于公司修订<对外担保管理制度>的议案》； 上海市青浦区徐泾镇高光路 169 弄虹桥时代广场 6 号楼荣泰大厦公司会议 室 三、会议主持人 1 上海荣泰健康科技股份有限公司董事长林光荣先 ...

股 票 代 码 ： 603579 股 票 简 称 ： 荣 泰 健 康 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 2024 年半年度业绩交流会会议纪要 一、时间： 2024 年 8 月 28 日上午 9 点，2024 年 8 月 28 日下午 15 点 二、调研方式：电话会议 三、调研机构及人员： | 序号 | 机构名称 | 人员姓名 | | --- | --- | --- | | 1 | 国泰君安 | 蔡雯娟 | | 2 | 国泰君安 | 李汉颖 | | 3 | 国泰君安 | 樊夏俐 | | 4 | 国泰君安 | 曲世强 | | 5 | 国泰君安 | 谢丛睿 | | 6 | 前海开源基金 | 曲羿铭 | | 7 | 上海峰境私募基金管理有限公司 | 黄宁 | | 8 | 同泰基金管理有限公司 | 唐之超 | | 9 | 广发基金管理有限公司 | 朱琪 | | 10 | 润晖投资管理香港有限公司 | 李勇 | | 11 | 北信瑞丰基金管理有限公司 | 张文博 | | 12 | 西部利得基金管理有限公司 | 朱清乐 | 3 | 序号 | 机构名称 | 人员姓名 | | --- | ...

托理财投资受到市场波动的影响。公司将根据经济形势以及金融市场的变化 适时适量地介入，因此短期投资的实际收益不可预期。 一、本次现金管理的情况概述 （一）现金管理目的 | 证券代码：603579 | 证券简称：荣泰健康 公告编号：2024-064 | | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | 上海荣泰健康科技股份有限公司 关于使用可转债闲置募集资金进行现金管理的进展 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资种类：可转让大额存单 投资金额：人民币 3,000 万元 现金管理期限：持有该存单期限不超过 12 个月 已履行的审议程序：上海荣泰健康科技股份有限公司（以下简称"公司"） 于 2024 年 4 月 15 日召开第四届董事会第十四次会议、第四届监事会第十一 次会议，于 2024 年 5 月 8 日召开 2023 年年度股东大会，分别审议通过了 《关于公司 2024 年度使用可转债闲置募集资金进行现金管理的议案》，同 意公司及子公司使用最高不超过人民币 ...

Investment Rating - The investment rating for the company is "Buy-A" with a target price of 15.12 CNY for the next six months, based on a 12x PE ratio for 2024 [2][4]. Core Views - The company reported a revenue of 820 million CNY for the first half of 2024, a year-over-year decrease of 7.3%, while the net profit attributable to shareholders was 110 million CNY, an increase of 6.1% year-over-year. In Q2 2024, the revenue was 420 million CNY, down 15.8% year-over-year, and the net profit was 50 million CNY, down 27.9% year-over-year. The report indicates that domestic consumer sentiment remains weak, and overseas orders have been affected by rising shipping costs, leading to short-term operational pressure [1][2]. Summary by Sections Financial Performance - The company’s Q2 revenue showed a decline, with domestic sales affected by low consumer confidence and a year-over-year drop of 32.3% in online sales across major platforms. Internationally, demand varied by region, with some markets like Korea recovering while others like the US faced challenges due to increased shipping costs [1]. - The Q2 net profit margin was 11.5%, down 1.9 percentage points year-over-year, primarily due to increased expense ratios and reduced revenue leading to diminished economies of scale. The gross margin also decreased by 2.3 percentage points year-over-year [1][7]. - Operating cash flow for Q2 was 110 million CNY, a decrease of 25.0% year-over-year, attributed to reduced sales volume [1]. Future Outlook - The company is expected to improve its domestic sales channels and expand its overseas market presence, which could lead to a recovery in revenue growth. EPS forecasts for 2024, 2025, and 2026 are 1.26 CNY, 1.49 CNY, and 1.73 CNY respectively [2][9]. - The projected revenue growth rates for the upcoming years are expected to be 1.8% in 2024, 14.9% in 2025, and 13.3% in 2026, indicating a gradual recovery [9]. Valuation Metrics - The company’s projected PE ratios are 13.7 for 2022, 11.1 for 2023, and 10.0 for 2024, suggesting a decreasing trend in valuation multiples as earnings are expected to grow [9][10]. - The net profit margin is projected to improve from 10.9% in 2023 to 12.6% in 2026, reflecting anticipated operational efficiencies and revenue growth [9].

Financial Performance - The company achieved a net profit attributable to shareholders of RMB 111,336,627.48 for the first half of 2024, representing a 6.12% increase compared to RMB 104,917,854.04 in the same period last year[4]. - Total revenue for the first half of 2024 was RMB 824,918,018.49, a decrease of 7.30% from RMB 889,901,502.72 in the previous year[19]. - The net profit attributable to shareholders was 111 million RMB, an increase of 6.12% year-on-year[38]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was 101 million RMB, up 5.90% from the previous year[38]. - Basic earnings per share for the current period is CNY 0.64, a 6.67% increase compared to CNY 0.60 in the same period last year[20]. - Diluted earnings per share decreased by 3.33% to CNY 0.58 from CNY 0.60 year-over-year[20]. - The total comprehensive income attributable to the parent company was CNY 92,463,894.56, compared to CNY 104,989,090.60 in the previous year, reflecting a decrease of 11.9%[111]. - The company reported a total comprehensive income of 66,908,306.85 RMB for the current period, reflecting a significant financial performance[129]. Cash Flow and Liquidity - The net cash flow from operating activities was negative RMB 43,184,531.68, a significant decline of 126.32% compared to a positive cash flow of RMB 164,083,652.44 in the same period last year[19]. - The company’s operating cash flow net amount decreased by 126.32% to -43.18 million RMB due to reduced revenue and increased payment cycles for raw materials[45]. - Cash inflows from operating activities totaled CNY 883,173,343.03, down from CNY 974,956,396.15 in the first half of 2023, indicating a decline of 9.4%[114]. - The net cash flow from operating activities for the first half of 2024 was -28,680,436.82 RMB, an improvement from -117,491,668.47 RMB in the same period of 2023[116]. - The ending cash and cash equivalents balance decreased to 326,064,981.97 RMB from 747,665,583.23 RMB in the previous year, representing a decline of approximately 56%[116]. - The company’s cash and cash equivalents decreased by 57.58% to ¥587,007,518.31, accounting for 17.58% of total assets[46]. Assets and Liabilities - The company's total assets at the end of the reporting period were RMB 3,338,173,352.09, down 1.38% from RMB 3,384,898,669.64 at the end of the previous year[19]. - The company's total liabilities were CNY 1.38 billion, a slight decrease from CNY 1.41 billion at the end of 2023[104]. - The company's equity attributable to shareholders was CNY 1.95 billion, down from CNY 1.97 billion at the end of 2023[104]. - The company's current assets totaled CNY 1.94 billion, a decrease from CNY 2.23 billion as of December 31, 2023[102]. - The company's total assets decreased to CNY 3,057,511,398.28 from CNY 3,147,476,703.63, reflecting a decline of 2.8%[107]. - The company's total liabilities decreased to CNY 1,436,467,331.82, down from CNY 1,483,373,579.25, a reduction of 3.2%[107]. Investments and Capital Structure - The company plans to increase its share capital by 30% through a capital reserve transfer, raising the total share capital to 179,377,241 shares[20]. - The company has made equity investments totaling ¥33,000 million in Zhejiang Rongtai Health Electric Co., Ltd., holding a 100% stake[50]. - The company has invested ¥16,099.46 million in Shanghai Airongda Fitness Technology Co., Ltd., also holding a 100% stake[50]. - The company has committed a total investment of RMB 59,398.23 million in the Huzhou Nanxun Rongtai Massage Chair Manufacturing Base project, with an actual investment of RMB 2,167.31 million in the current year, representing a progress of 15.35%[54]. - The company raised a total of CNY 600 million through convertible bonds, with a net amount of CNY 593,982,329.04 after deducting issuance costs[80]. - The total number of shares increased from 138,974,371 to 179,377,241 after issuing new shares[85]. Research and Development - The company completed 15 R&D projects and obtained 10 invention patents, 10 utility model patents, and 14 design patents during the reporting period[41]. - The company’s R&D expenses increased by 2.29% to 38.12 million RMB, mainly due to higher salaries for R&D personnel[44]. - Research and development expenses increased slightly to CNY 38,122,653.47, compared to CNY 37,267,618.96 in the previous year[110]. Market and Industry - The company operates in the massage equipment industry, which is closely tied to global economic conditions and consumer health awareness[24]. - The main business includes the design, research and development, production, and sales of massage equipment, aiming to provide a healthy lifestyle for users[25]. - The company is actively expanding its market presence and has signed a land purchase agreement in Thailand to enhance its production capabilities[42]. - The company’s international orders have shown mixed performance, with significant recovery in the European and Middle Eastern markets, while the Korean market experienced a notable decline in the first quarter[39]. Shareholder and Governance - The company plans to distribute a cash dividend of RMB 3.00 per 10 shares (including tax) based on the total share capital on the dividend distribution date[4]. - The company has approved a plan for the 2024 employee stock ownership plan, details of which are available on the Shanghai Stock Exchange website[71]. - The total number of ordinary shareholders reached 11,752 by the end of the reporting period[89]. - The largest shareholder, Lin Qi, holds 45,370,299 shares, accounting for 25.29% of the total shares[89]. - The company has not reported any changes in the voting rights of shareholders or any related party transactions among the top shareholders[91]. Risks and Challenges - The company faces risks from raw material price fluctuations, as over 80% of its cost structure is comprised of raw materials, which could impact net profit growth if prices rise significantly[63]. - The competitive landscape in the massage equipment market is intensifying, prompting the company to increase R&D investment and focus on brand promotion to maintain market share[67]. - The company is exposed to foreign exchange risks due to its export business primarily being settled in USD, and it plans to manage this risk through various strategies[66]. Legal and Compliance - The company has not reported any significant litigation or arbitration matters during the reporting period[75]. - The company has not received any penalties or corrective actions related to legal violations during the reporting period[75]. - The company has committed to avoid competition with its controlling shareholders until October 2026[73]. Accounting and Financial Reporting - The company’s financial statements are prepared in accordance with the accounting standards issued by the Ministry of Finance[140]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired in a business combination[147]. - The company applies the equity method for investments in joint ventures, recognizing its share of assets, liabilities, income, and expenses accordingly[152]. - The company recognizes financial assets and liabilities at fair value on the transaction date when it becomes a party to a financial instrument contract[156].

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603579 证券简称：荣泰健康 公告编号：2024-058 转债代码：113606 转债简称：荣泰转债 上海荣泰健康科技股份有限公司 一、募集资金基本情况 （一）实际募集资金金额、资金到账时间 关于2024年半年度募集资金存放与实际使用情况的专 项报告 | | | 1 | 年 2023 31 | 12 | 月 | 日募集资金专户余额 | 32,039.07 | | --- | --- | --- | --- | --- | | 减：募集资金投资项目本期投入资金 | | | | 2,167.31 | | 减：暂时闲置募集资金购买大额存单 | | | | 43,000.00 | | 加：赎回大额存单 | | | | 30,000.00 | | 加：2024 年 | | 1-6 | 月扣除手续费后存款利息收入 | 270.68 | | 加：2024 年 | | 1-6 | 月理财产品投资收益 | 262.66 | | 2024 年 月 | 6 | 30 | 日募集资金专户余 ...

上海荣泰健康科技股份有限公司 对外担保管理制度 第一章 总 则 第一条 为了规范上海荣泰健康科技股份有限公司（以下简称"公司"）的对 外担保行为，根据《中华人民共和国民法典》（以下简称《民法典》）、《中华人民 共和国公司法》（以下简称《公司法》）、《中华人民共和国证券法》（以下简称《证 券法》）、《上海证券交易所股票上市规则》等法律法规、规范性文件，以及《上海 荣泰健康科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定，结合 公司的实际情况，特制定本制度。 第二条 本制度适用于本公司及本公司的全资子公司、控股子公司（以下共同 简称"子公司"）。 第九条 公司可以为具有独立法人资格和较强偿债能力并具有以下条件之一 的单位提供担保： （一）因公司业务需要的互保单位； （二）与公司具有重要业务关系的单位； 第四条 子公司的对外担保，视同公司行为，其对外担保应执行本制度，并应 获得公司董事会批准。公司子公司在其董事会或股东会做出决议后应及时通知公 司董事会秘书。 第五条 公司对外担保实行统一管理，非经公司董事会或股东大会批准，任何 人无权以公司名义签署对外担保的合同、协议或其他类似的法律文件。 第六条 公司 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2024-060 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于变更公司 2021 年回购股份用途暨注销部分回购 股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性 陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 4、回购资金来源：公司自有资金。 一、变更前回购方案概述 公司于2021年2月4日召开第三届董事会第十次会议及第三届监事会第十次 变更前回购股份用途：用于股权激励及员工持股计划。 变更后回购股份用途：用于注销并减少公司注册资本。 上海荣泰健康科技股份有限公司（以下简称"公司"）拟注销回购专用 证券账户中 2021 年回购股份方案已回购的 1,995,479 股股份，注销完成 后公司总股本将由 179,377,241 股变更为 177,381,762 股，注册资本将 由 179,377,241 元变更为 177,381,762 元。本次变更回购股份用途及注 销事项尚需提交公司股东大会审议 ...

| 证券代码：603579 | 证券简称：荣泰健康 | 公告编号：2024-062 | | --- | --- | --- | | 转债代码：113606 | 转债简称：荣泰转债 | | 上海荣泰健康科技股份有限公司 关于注销部分回购股票通知债权人的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、通知债权人的原由 上海荣泰健康科技股份有限公司（以下简称"公司"）于2024年8月27日召 开第四届董事会第十七次会议及第四届监事会第十三次会议，审议通过了《关于 变更公司2021年回购股份用途暨注销部分回购股份的议案》以及《关于变更注册 资本及修订<公司章程>的议案》。以上议案还需经过股东大会审议。具体回购注 销情况如下： （一）本次注销回购股票的相关规定及注销股份数量 公司于 2021 年 2 月 4 日召开第三届董事会第十次会议及第三届监事会第十 次会议，逐项审议通过了《关于回购公司股份预案的议案》。回购股份规模：不 低于人民币 5,000 万元（含 5,000 万元），不超过人民币 10,000 万元（含 10,00 ...